Gonadorelin
A synthetic decapeptide identical to native gonadotropin-releasing hormone, FDA approved as Factrel in 1982 for pituitary testing and as Lutrepulse in 1989 for ovulation induction, with both US products since discontinued.
Also referenced as: Gonadotropin-Releasing Hormone, GnRH, LHRH, Gonadorelin hydrochloride, Gonadorelin acetate, Factrel, Lutrepulse
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the latest vendor-default policy recorded for that UTC day. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Gonadorelin crosses your target, drops, or sets a new tracked low—without daily noise.
This compound maps to at least one regulated medical product or label context in the United States.
This profile is grouped by its dominant research area, not by vendor shelf placement.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
Gonadotropin-Releasing Hormone, GnRH, LHRH, Gonadorelin hydrochloride, Gonadorelin acetate, Factrel, Lutrepulse
No FDA label signal · 150 trials · 299 PubMed results
Gonadorelin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Gonadorelin has no clinical trials that name it and 299 PubMed-indexed publications and holds an FDA drug label. Current evidence is preclinical or mechanistic.
- 2026-11-01 Preclinical → Established Band Preclinical → Established; +2 PubMed
- 2026-07-09 Preclinical First graded
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-07 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What gonadorelin is
Gonadorelin is a gonadotropin-releasing hormone analogue tied to reproductive endocrine signaling. It occupies a more medically grounded hormone lane than most retail-market peptides, even though it also shows up in vendor catalogs.
Why it matters
It helps round out the hormone category with a peptide centered on pituitary and reproductive signaling rather than growth hormone or cosmetic use.
Regulatory context
Gonadorelin has two FDA-approved US products on record. Factrel (gonadorelin hydrochloride for injection), NDA 018123, was approved on September 30, 1982 as a diagnostic agent for testing the gonadotropin-releasing capacity of the anterior pituitary, and Lutrepulse (gonadorelin acetate), NDA 019687, was approved on October 10, 1989 for pulsatile-pump induction of ovulation in women with hypothalamic amenorrhea (Santoro, American Journal of Obstetrics and Gynecology, 1990). The FDA Approved status reflects those two applications, which Drugs@FDA still lists as approved. Every Factrel and Lutrepulse product is marked discontinued and no gonadorelin product is currently marketed for human use in the US, so the approval history does not make retail listings, veterinary gonadorelin products or compounded preparations interchangeable with an approved drug.
Practical reading note
When a hormone peptide has real medical or diagnostic history, the safest move is to distinguish that history from the way it is repackaged in the research market.